IBRX · ImmunityBio, Inc.
$7.91
+2.46% last session
End-of-day data · close of 2026-09-11
Market cap
$8B
Enterprise value
$9B
Trailing P/E
—
Forward P/E
-61.0
Dividend yield
—
Beta
0.14
Avg volume
10M
Employees
1K
Daily Change %
2.46%
5 Days Change
-0.25%
10 Days Change
1.38%
30 Days Change
6.05%
60 Days Change
-1.95%
Month to Day Change
2.41%
Year to Day Change
307.07%
Analyst Outlook
Analyst estimates change daily — follow the shifts on the Estimate Trends page.
Technical Analysis
Analyst sentiment over time — IBRX
Rec Mean (blue, left — higher = more bullish) vs. price targets (right).
Investment Bank Ratings as of 2026-06-02
Latest call per bank · past 12 months
Jefferies
Buy$9.00
+16.6% vs priceRecent rating actions
| Date | Firm | Action | Rating | Price target |
|---|---|---|---|---|
| 2026-06-02 | HC Wainwright & Co. | Reiterates | Buy | $15.00 |
| 2026-05-21 | BTIG | Reiterates | Buy | $12.00 |
| 2026-05-20 | HC Wainwright & Co. | Reiterates | Buy | $15.00 |
| 2026-05-05 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-04-21 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-04-08 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-03-26 | D. Boral Capital | Maintains | Buy | $23.00 |
| 2026-03-23 | D. Boral Capital | Maintains | Buy | $23.00 |
Ratings and price targets are the published opinions of the issuing banks, compiled from Yahoo Finance rating actions — not investment advice.
Signal Summary as of 2026-09-11
- RSI (14): RSI is 50 — neutral momentum, neither overbought nor oversold.
- Price vs 50-day MA: Trading 1.1% above the 50-day MA ($7.82).
- Price vs 200-day MA: Trading 17.7% above the 200-day MA ($6.72).
- MA cross: The 50-day MA sits above the 200-day MA (golden-cross regime) — the longer-term trend points up.
- MACD (12,26,9): MACD histogram is negative (-0.03) — short-term momentum is fading.
- 52-week range: Price sits between the 52-week low ($1.98) and high ($11.55).
IBRX Price Chart
Loading chart for IBRX…
Fundamentals
About ImmunityBio, Inc.
ImmunityBio, Inc., a biotechnology company, focuses on innovating, developing, and commercializing next-generation immunotherapies designed to activate the patient's immune system and deliver durable protection against cancer and infectious diseases. Its platforms for the development of biologic products and product candidates that include cytokine fusion proteins, DNA and vaccine vectors, and cell therapies. The company's platform has generated first-in-human therapeutic agents that are planned to be studied in clinical trials in liquid and solid tumors. Its lead biologic product candidate includes Anktiva, an FDA-approved immunotherapy in combination with bacillus calmette-guérin (BCG) for the treatment of adult patients with BCG unresponsive non-muscle invasive bladder cancer with carcinoma in situ, with or without papillary tumors; and 3M-052, a synthetic TLR7/8 agonist and 3M-052 formulations and related technology. The company has collaboration agreements with National Cancer Institute; Serum Institute of India Private Limited; and BeOne Medicines Ltd. It has license agreement with 3M Innovative Properties Company and Access to Advanced Health Institute. ImmunityBio, Inc. is based in San Diego, California.
More in Biotechnology
VRTX
Vertex Pharmaceuticals Incorpor
$130B 14.9% YTD
REGN
Regeneron Pharmaceuticals, Inc.
$82B 5.0% YTD
ARGX
argenx SE
$62B 19.2% YTD
MRNA
Moderna, Inc.
$55B 359.9% YTD
RVMD
Revolution Medicines, Inc.
$44B 160.7% YTD
ONC
BeOne Medicines Ltd.
$39B 15.5% YTD
RPRX
Royalty Pharma plc
$34B 59.0% YTD
ALNY
Alnylam Pharmaceuticals, Inc.
$33B -35.1% YTD
Data is sourced from end-of-day snapshots and refreshed daily before the US market open — nothing on this page is real-time. Figures can contain vendor errors. This page is for information only and is not investment advice.